To clarify the complementary roles of the ASMBS/IFSO guidelines for metabolic-bariatric surgery eligibility and the diagnostic framework proposed by the 2025 Lancet Diabetes & Endocrinology Commission, emphasizing the need for integration.
Key Findings:
The ASMBS/IFSO guidelines broaden access to metabolic-bariatric surgery by recognizing limitations of BMI as a sole criterion, which can lead to improved patient care.
The Lancet Commission emphasizes a functional definition of obesity, enhancing diagnosis and patient outcomes.
Both frameworks are complementary, addressing different aspects of obesity care: eligibility for treatment and disease definition, which together can improve clinical decision-making.
Interpretation:
Integrating the ASMBS/IFSO guidelines with the Lancet Commission's framework supports a proportional, risk-stratified approach to obesity care, ensuring timely and equitable treatment, which is crucial for effective management.
Limitations:
Scarcity of high-quality evidence supporting surgery for patients with BMI >35 kg/m² without comorbidities or functional impairment, which raises concerns about the robustness of treatment recommendations.
Much of the support for this population is based on subgroup analyses and observational studies, indicating a need for further research.
Conclusion:
A unified understanding of diagnostic and therapeutic frameworks can enhance clinical practice in obesity management, promoting earlier intervention and monitoring, which is essential for improving patient outcomes.
